시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 레드 바이오테크놀러지 시장 보고서(2025년)
Red Biotechnology Global Market Report 2025
상품코드 : 1825890
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,516,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,419,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

레드 바이오테크놀러지 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 10.5%로 9,378억 5,000만 달러로 성장할 것입니다. 예측 기간의 성장 배경에는 맞춤형 의료의 확대, 고령화, 연구개발 투자, 디지털 헬스 통합, 헬스케어 인프라 확대 등이 있습니다. 예측 기간의 세계 트렌드에는 생물학적 제제 및 바이오시밀러의 확대, 머신러닝의 통합, 마이크로바이옴 기반 치료제 개발, 희귀질환 및 희귀질환에 대한 집중, 세계 협력 및 파트너십 등이 포함됩니다.

향후 5년간 10.5%의 성장률 전망은 지난번 추정치보다 0.7% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 스웨덴과 중국에서 수입되는 CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 유전자 편집 키트에 대한 접근을 제한하고, 재생의료 임상시험을 지연시키며, 치료제 개발비용을 증가시킬 수 있습니다. 미국 바이오제약에 큰 도전이 될 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

레드 바이오테크놀러지 시장은 맞춤형 의료에 대한 수요 증가로 인해 성장할 것으로 보입니다. 개인맞춤의료는 유전, 생활습관 등 개인의 특성에 맞는 치료를 통해 효과를 최적화하고 부작용을 줄이는 것입니다. 이러한 수요는 보다 효과적인 치료의 가능성, 유전체학의 발전, 질병의 복잡성, 지원적 규제에 의해 촉진되고 있습니다. 레드 바이오테크놀러지는 유전자 정보를 활용하여 환자의 유전자 프로파일과 질병 특성에 따라 맞춤형 치료를 제공함으로써 맞춤형 의약품 개발을 촉진합니다. 예를 들어, 2024년 2월 FDA는 희귀질환에 대한 새로운 맞춤형 치료제를 2022년 6건, 2023년 16건을 승인했다고 맞춤형의료연합은 보고했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Red biotechnology, a branch of biotechnology, focuses on medical and pharmaceutical applications, utilizing biological systems and organisms to develop products and technologies for healthcare. These include pharmaceuticals, diagnostic tests, and therapies to treat diseases and enhance human health.

The main products in red biotechnology encompass monoclonal antibodies, polyclonal antibodies, recombinant proteins, vaccines, cell-based immunotherapy products, gene therapy products, cell therapy products, tissue-engineered products, among others. Monoclonal antibodies, for instance, are lab-made proteins that mimic the immune system's ability to combat pathogens, finding application in targeted therapies for conditions such as cancer and autoimmune disorders. Red biotechnology spans drug discovery, animal biotechnology, environmental biotechnology, medical biotechnology, industrial biotechnology, agricultural biotechnology, catering to end-users such as the biopharmaceutical industry, contract manufacturing organizations (CMOs), contract research organizations (CROs), research institutes, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The red biotechnology market research report is one of a series of new reports from The Business Research Company that provides red biotechnology market statistics, including the red biotechnology industry global market size, regional shares, competitors with the red biotechnology market share, detailed red biotechnology market segments, market trends, and opportunities, and any further data you may need to thrive in the red biotechnology industry. These red biotechnology market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The red biotechnology market size has grown rapidly in recent years. It will grow from $566.28 billion in 2024 to $629.69 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to advancements in genetic engineering, stem cell research, growth of biotech startups, regulatory frameworks, biotech funding, and investment.

The red biotechnology market size is expected to see rapid growth in the next few years. It will grow to $937.85 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to the expansion of personalized medicine, the aging population, investment in research and development, digital health integration, and the expansion of healthcare infrastructure. Major trends in the forecast period include the expansion of biologics and biosimilars, integration of machine learning, development of microbiome-based therapies, focus on rare and orphan diseases, global collaboration, and partnerships.

The forecast of 10.5% growth over the next five years reflects a modest reduction of 0.7% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. biopharma by restricting access to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 gene editing kits imported from Sweden and China, potentially stalling regenerative medicine trials and increasing therapeutic development costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The red biotechnology market is set to experience growth, driven by the increasing demand for personalized medicine. Personalized medicine tailors medical treatment to individual characteristics such as genetics or lifestyle to optimize effectiveness and reduce adverse effects. This demand is fueled by the potential for more effective treatments, advances in genomics, growing disease complexities, and supportive regulations. Red biotechnology facilitates the development of personalized medicines by leveraging genetic information to customize treatments based on a patient's genetic profile and disease attributes. For example, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases in 2023, compared to six in 2022, as reported by the Personalized Medicine Coalition.

Leading companies in the red biotechnology sector are concentrating on developing innovative products such as biosimilars to cater to the rising demand for personalized medicine and tackle disease complexities. Biosimilars are biological products closely resembling existing approved reference biologics, offering cost-effective alternatives. For instance, in June 2022, Amgen Inc. obtained FDA approval for Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab), for treating adults with moderate to severe rheumatoid arthritis (RA). This milestone underscores the development of biosimilars, designed to mimic existing biological products at lower costs.

In March 2023, Ipsen Biopharmaceuticals Inc. acquired Albireo Pharma Inc. to enhance its Rare Disease portfolio with therapies for rare cholestatic liver diseases. Albireo Pharma Inc. specializes in novel bile acid modulators for orphan pediatric liver diseases, contributing to Ipsen's scientific and commercial capabilities.

Major companies operating in the red biotechnology market are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Amgen Inc., Merck KGaA, Moderna Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Boehringer Ingelheim International GmbH, BioMarin Pharmaceutical Inc., Vir Biotechnology, Alnylam Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, BioCryst Pharmaceuticals, Sangamo Therapeutics, Inc., Denali Therapeutics, Atara Biotherapeutics, Beam Therapeutics, Umoja Biopharma

North America was the largest region in the red biotechnology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the red biotechnology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the red biotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The red biotechnology market consists of sales of diagnostic testing kits, biological sensors, regenerative medicine, and antibiotics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Red Biotechnology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on red biotechnology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for red biotechnology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The red biotechnology market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Red Biotechnology Market Characteristics

3. Red Biotechnology Market Trends And Strategies

4. Red Biotechnology Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Red Biotechnology Growth Analysis And Strategic Analysis Framework

6. Red Biotechnology Market Segmentation

7. Red Biotechnology Market Regional And Country Analysis

8. Asia-Pacific Red Biotechnology Market

9. China Red Biotechnology Market

10. India Red Biotechnology Market

11. Japan Red Biotechnology Market

12. Australia Red Biotechnology Market

13. Indonesia Red Biotechnology Market

14. South Korea Red Biotechnology Market

15. Western Europe Red Biotechnology Market

16. UK Red Biotechnology Market

17. Germany Red Biotechnology Market

18. France Red Biotechnology Market

19. Italy Red Biotechnology Market

20. Spain Red Biotechnology Market

21. Eastern Europe Red Biotechnology Market

22. Russia Red Biotechnology Market

23. North America Red Biotechnology Market

24. USA Red Biotechnology Market

25. Canada Red Biotechnology Market

26. South America Red Biotechnology Market

27. Brazil Red Biotechnology Market

28. Middle East Red Biotechnology Market

29. Africa Red Biotechnology Market

30. Red Biotechnology Market Competitive Landscape And Company Profiles

31. Red Biotechnology Market Other Major And Innovative Companies

32. Global Red Biotechnology Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Red Biotechnology Market

34. Recent Developments In The Red Biotechnology Market

35. Red Biotechnology Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기